Literature DB >> 8717164

Effects of the class III antiarrhythmic drug ambasilide on outward currents in human atrial myocytes.

B Koidl1, P Flaschberger, P Schaffer, B Pelzmann, E Bernhart, H Mächler, B Rigler.   

Abstract

We have studied the inhibitory influence of the class III antiarrhythmic drug ambasilide (LU 47110) on the transient outward current Ito1 and the sustained current Iso following inactivation of Ito1, in human atrial myocytes. The two currents are separated by a mathematical procedure based on the amplitudes and time constants of the biexponential inactivation of the total outward current. The frequency dependence, the recovery from inactivation and the kinetics of activation and inactivation are described. Ambasilide reversibly and concentration dependently inhibited Ito1, Iso and the sodium current INa. Concentration required for half maximal inhibition (IC50) for the effects on Ito1 and Iso were 23.3 mumol/l and 45.7 mumol/l respectively, concentrations shown by others to be effective in terminating and preventing fibrillation in a dog atrial arrhythmia model. Ambasilide not only reduced the amplitude of Ito1 and Iso but also accelerated the time course of inactivation from 14.22 to 6.69 ms and from 202.3 to 87.9 ms respectively. The amplitude of Ito1 showed only a small dependence on stimulation frequency characteristic for human atrial myocytes, whereas Iso was reduced significantly at higher stimulation frequencies. Ambasilide did not change these relationships (0.1-4 Hz) and therefore did not show the reverse use-dependence known from other class III antiarrhythmic agents and which is an important property for a prospective antiarrhythmic drug. The lack of an effect of ambasilide on both steady-state activation and inactivation of Ito1, and the time constant of recovery from inactivation, suggests that ambasilide acts by changing conductance rather than by influencing the gating mechanism. The described characteristics make ambasilide an interesting substance in the group of class III antiarrhythmic drugs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8717164     DOI: 10.1007/BF00168761

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  28 in total

1.  Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence.

Authors:  L M Hondeghem; D J Snyders
Journal:  Circulation       Date:  1990-02       Impact factor: 29.690

2.  Contributions of a transient outward current to repolarization in human atrium.

Authors:  E F Shibata; T Drury; H Refsum; V Aldrete; W Giles
Journal:  Am J Physiol       Date:  1989-12

3.  Depressed transient outward and calcium currents in dilated human atria.

Authors:  B L Le Grand; S Hatem; E Deroubaix; J P Couétil; E Coraboeuf
Journal:  Cardiovasc Res       Date:  1994-04       Impact factor: 10.787

4.  K+ channel blocking actions of flecainide compared with those of propafenone and quinidine in adult rat ventricular myocytes.

Authors:  M T Slawsky; N A Castle
Journal:  J Pharmacol Exp Ther       Date:  1994-04       Impact factor: 4.030

5.  Class III antiarrhythmic drug action in experimental atrial fibrillation. Differences in reverse use dependence and effectiveness between d-sotalol and the new antiarrhythmic drug ambasilide.

Authors:  J Wang; J Feng; S Nattel
Journal:  Circulation       Date:  1994-10       Impact factor: 29.690

6.  Transient outward current in human and rat ventricular myocytes.

Authors:  E Wettwer; G Amos; J Gath; H R Zerkowski; J C Reidemeister; U Ravens
Journal:  Cardiovasc Res       Date:  1993-09       Impact factor: 10.787

7.  Differences in rate dependence of transient outward current in rabbit and human atrium.

Authors:  B Fermini; Z Wang; D Duan; S Nattel
Journal:  Am J Physiol       Date:  1992-12

8.  Adenosine inhibits the L-type calcium current in human atrial myocytes.

Authors:  B Pelzmann; P Schaffer; H Mächler; B Rigler; B Koidl
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-03       Impact factor: 3.000

9.  Different mechanisms of the inhibition of the transient outward current in rat ventricular myocytes.

Authors:  U Jahnel; P Klemm; H Nawrath
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-01       Impact factor: 3.000

10.  Transient outward current in human ventricular myocytes of subepicardial and subendocardial origin.

Authors:  E Wettwer; G J Amos; H Posival; U Ravens
Journal:  Circ Res       Date:  1994-09       Impact factor: 17.367

View more
  4 in total

1.  The sulphonylurea glibenclamide inhibits voltage dependent potassium currents in human atrial and ventricular myocytes.

Authors:  P Schaffer; B Pelzmann; E Bernhart; P Lang; H Mächler; B Rigler; B Koidl
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

2.  Xenoreactive natural antibodies and induced antibodies--their effects of beating cardiomyocytes as a model of a xenograft.

Authors:  U Müller-Werdan; B Koidl; A Autenrieth; D Klein; K Werdan; C Hammer
Journal:  Mol Cell Biochem       Date:  1996 Jul-Aug       Impact factor: 3.396

3.  Rate-Dependent Role of IKur in Human Atrial Repolarization and Atrial Fibrillation Maintenance.

Authors:  Martin Aguilar; Jianlin Feng; Edward Vigmond; Philippe Comtois; Stanley Nattel
Journal:  Biophys J       Date:  2017-05-09       Impact factor: 4.033

Review 4.  Cardiac Potassium Channels: Physiological Insights for Targeted Therapy.

Authors:  Kamalan Jeevaratnam; Karan R Chadda; Christopher L-H Huang; A John Camm
Journal:  J Cardiovasc Pharmacol Ther       Date:  2017-09-25       Impact factor: 2.457

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.